Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Effect of Longer-term Ofatumumab Treatment on Disability Progression and Brain Volume Change

Author:Cohen, Jeffrey   Hauser, Stephen   Zielman, Ronald   Das Gupta, Ayan   Azmon, Amin   Xi, Jing   Mavrikis Cox, Gina   Robertson, Derrick   Wiendl, Heinz   Kappos, Ludwig   

Session Name:S16: MS Clinical Trials and Therapeutics  

Topic:MS and Inflammatory Disease  

Program Number:S16.009  

Author Institution:Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  UCSF Weill Institute for Neurosciences, Department of Neurology, University of California - San Francisco, San Francisco, CA, USA, San Francisco, CA  Central Texas Neurology Consultants, Round Rock, TX, USA, Round Rock, TX  Novartis Pharma B.V., Amsterdam, The Netherlands, Haaksbergweg, Netherlands  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharma A.G., Basel, Switzerland, Basel, Switzerland  China Novartis Institutes for BioMedical Research Co., Ltd, Shanghai, China, Shanghai, China, People's Republic of  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL, USA, Tampa, FL  University of Muenster, Muenster, Germany, Muenster, Germany  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  

Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis

Author:Cohen, Jeffrey   Hauser, Stephen   Cross, Anne   Winthrop, Kevin   Wiendl, Heinz   Nicholas, Jacqueline   Meuth, Sven   Giacomini, Paul   Sacca, Francesco   Zielman, Ronald   Das Gupta, Ayan   Hu, Xixi   Sullivan, Roseanne   DeLasHeras, Virginia   Kappos, Ludwig   

Session Name:P8: MS Therapeutics 2  

Topic:MS and Inflammatory Disease  

Program Number:P8.004  

Author Institution:Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA  Washington University School of Medicine, Saint Louis, MO, USA, Clayton, MO  Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR, USA, Portland, OR  University of Muenster, Muenster, Germany, Muenster, Germany  OhioHealth Multiple Sclerosis Center, Columbus, OH, USA, Columbus, OH  Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany, Duesseldorf, Germany  Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada  NSRO Department, University “Federico II” of Naples, Naples, Italy, Napoli, Italy  Novartis Pharma B.V., Amsterdam, The Netherlands, Haaksbergweg, Netherlands  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Morristown, NJ  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland